The selective σ2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1323-1332

  Sanchez C ^a   Arnt, J ^a   Costall, B ^b   Kelly, M E ^b   Meier, E ^a   Naylor, R J ^b   Perregaard, J ^a  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROPHENYL) 3 [4[4 (4 FLUOROPHENYL) 1 PIPERIDINYL] 1 BUTYL] 1H INDOLE; ANXIOLYTIC AGENT; DIAZEPAM; HALOPRENDOL; LORAZEPAM; LU 28 179; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; LU 28-179; SIGMA OPIATE RECEPTOR; SPIRO COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG ELIMINATION; DRUG POTENCY; DRUG WITHDRAWAL; INTRAVENOUS DRUG ADMINISTRATION; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SEDATION; SHOCK; SOCIAL INTERACTION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANQUILIZING ACTIVITY; VOCALIZATION; ANIMAL; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MALE; MICE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SPIRO COMPOUNDS; VOCALIZATION, ANIMAL;

EID: 0031283066     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. 1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. J. Med. Chem. 38: 4380-4392, 1995.
2. 1 binding sites in guinea pig brain. Eur. J. Pharmacol. 251: R1-R2, 1994.
3. CLISSOLD, D. B., PONTECORVO, M. J., JONES, B. E., ABREU, M. E., KARBON, E. W., ERICKSON, R. H., NATALIE, K. J., BOROSKY, S., HARTMAN, T., MANSBACH, R. S., BALSTER, R. L., FERKANY, J. W. AND ENNA, S. J.: NPC 16377, a potent and selective σ ligand. II. Behavioral and neuroprotective profile. J. Pharmacol. Exp. Ther. 265: 876-886, 1993.
4. COSTALL, B., DOMENEY, A. M., HUGHES, J., KELLY, M. E., NAYLOR, R. J. AND WOODRUFF, G. N.: Anxiolytic effects of CCK-B antagonists. Neuropeptides 19: 65-73, 1991.
5. COSTALL, B., JONES, B. J., KELLY, M. E., NAYLOR, R. J. AND TOMKINS, D. M.: Exploration of mice in a black and white test box: Validation as a model of anxiety. Pharmacol. Biochem. Behav. 22: 777-785, 1989.
6. CUOMO, V., CAGIANO, R., DE SALVIA, M. A., MASELLI, M. A., RENNA, G. AND RACAGNI, R.: Ultrasonic vocalization in response to unavoidable aversive stimuli in rats: Effects of benzodiazepines. Life Sci. 43: 485-491, 1988.
7. DE VRY, J., BENZ, U., SCHREIBER, R. AND TRABER, J.: Shock-induced ultrasonic vocalization in young adult rats: A model for testing putative anti-anxiety drugs. Eur. J. Pharmacol. 249: 331-339, 1993.
8. FILE, S. E.: The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Meth. 2: 219-238, 1980.
9. FILE, S. E.: Usefulness of animal models with newer anxiolytics. Clin. Neuropharm. 15: 525A-526A, 1992.
10. FREEDMAN, S. B., HARLEY, E. A. AND PATEL, S.: Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding. Eur. J. Pharmacol. 174: 253-260, 1989.
11. GILLIGAN, P. J., CAIN, G. A., CHRISTOS, T. E., COOK, L., DRUMMOND, S., JOHNSON, A. L., KERGAYE, A. A., MCELROY, J. F., ROHRBACH, K. W., SCHMIDT, W. K. AND TAM, S. W.: Novel piperidine sigma ligands as potential antipsychotic drugs. J. Med. Chem. 35: 4344-4361, 1992.
12. 1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in social interaction test, but not in the elevated plus-maze. Brain Res. 732: 145-153, 1996.
13. GRAEFF, F. G., VIANA, M. B. AND MORA, P. O.: Opposed regulation by dorsal raphe nucleus 5-HT pathways of two types of fear in the elevated T-maze. Pharmacol. Biochem. Behav. 53: 171-177, 1996.
14. 3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J. Neurosci. 6: 1757-1770, 1986.
15. 1 receptors in the brain. Life Sci. 34: 597-605, 1984.
16. HARRO, J., VASAR, E. AND BRADWEJN, J.: CCK in animal and human research on anxiety. Tr. Pharmacol. Sci. 14: 224-249, 1993.
17. B antagonists on activity in the black/white exploration model of anxiety in mice. Physiol. Behav. 54: 689-693, 1993.
18. HYTTEL, J.: Citalopram - pharmacological profile of a specific serotonin-uptake inhibitor with antidepressant activity. Prog. Neuro. Psychopharmacol. 6: 277-295, 1982.
19. 2 receptors in corpus striatum of rats. Pharmacol. Toxicol. 61: 126-129, 1987.
20. HYTTEL, J. AND LARSEN, J.-J.: Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline and serotonin. J. Neurochem. 44: 1615-1622, 1985.
21. HYTTEL, J., OVERØ, K. F. AND ARNT, J.: Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacol. 83, 2: 181-184, 1984.
22. 2-receptor antagonist. Drug Dev. Res. 15: 389-404, 1988.
23. 1 sites. Eur. J. Pharmacol. 299: 21-28, 1996.
24. KARBON, E. W., ABREU, M. E., ERICKSON, R. H., KAISER, C., NATALIE, K. J., CLISSOLD, D. B., BOROSKV, S., BAILEY, M., MARTIN, L. A., PONTECORVO, M. J., ENNA, S. J. AND FERKANY, J. W.: NPC 16377, a potent and selective σ ligand. I. Receptor binding, neurochemical and neuroendocrine profile. J. Pharmacol. Exp. Ther. 265: 866-875, 1993.
25. LAI, N. L., BOWEN, W. D., MATSUMOTO, R. R., THURKAUF, A., RICE, K. C. AND WALKER, J. M.: Anxiogenic effects of two selective sigma ligands in the rat. (Abstract) Soc. Neurosci. 15: 270.9, 1989.
26. LISTER, R. G.: Ethologically-based animal models of anxiety disorders. Pharm. Ther. 46: 321-340, 1990.
27. MCCANN, D. J., WEISSMAN, A. D. AND SU, T.-P.: Sigma-1 and sigma-2 sites in rat brain: Comparison of regional, ontogenetic, and subcellular patterns. Synapse 17: 182-189, 1994.
28. 2 selectivity of test compounds: (1) α-adrenoceptor antagonists. Eur. J. Pharmacol. 129: 49-55, 1986.
29. 3-antagonistic properties. Drug Dev. Res. 40: 1-16, 1997.
30. MONNET, F. P.: Implication des récepteurs sigma dans les syndromes schizophréniques. Approche physiopathologique. Press Médicale 22: 218-223, 1993.
31. OKUYAMA, S., IMAGAWA, Y., OGAWA, S., ARAKI, H., AJIMA, A., TANAKA, M., MURAMATSU, M., NAKAZATO, A., YAMAGUCHI, K., YOSHIDA, M. AND OTOMO, S.: NE-100, a novel sigma receptor ligand: In vivo tests. Life Sci. 53: PL 285-290, 1993.
32. ONAIVI, E. S. AND MARTIN, B. R.: Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Progr. Neuro Psychopharmacol. 13: 963-976, 1989.
33. PERREGAARD, J., SÁNCHEZ, C. AND ARNT, J.: Recent developments in anxiolytics. Cur. Opin. Ther. Pat. 2: 101-128, 1993.
34. 2 binding site. Part 1. 3-(ω-Aminoalkyl)-1H-indoles. J. Med. Chem. 38: 1998-2008, 1995.
35. PESOLD, C. AND TREIT, D.: The Central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 67: 213-221, 1995.
36. PETERSEN, E. N. AND LASSEN, J. B.: A water lick conflict paradigm using drug experienced rats. Psychopharmacology 75: 236-239, 1981.
37. QUIRION, R., BOWENS, W. D., ITZHAK, Y., JUNIEN, J. L., MUSACCHIO, J. M., ROTHMAN, R. B., SU, T. P., TAM, S. W. AND TAYLOR, D. P.: A proposal for the classification of sigma binding sites. Tr. Pharmacol. Sci. 13: 85-86, 1992.
38. SÁNCHEZ, C.: Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats. Behav. Pharmacol. 4: 269-277, 1993.
39. SÁNCHEZ, C.: Acute stress enhances anxiolytic-like drug responses of mice tested in a black and white test box. Eur. Neuropsychopharmacol., in press, 1997.
40. SÁNCHEZ, C., ARNT, J., HYTTEL, J. AND MOLTEN, E. G.: The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology 110: 53-59, 1993.
41. SÁNCHEZ, C., ARNT, J. AND PERREGAARD, J.: Lu 28-179 - A selective sigma ligand with potent anxiolytic effects (Abstract). Soc. Neurosci. 20: 164.16, 1994.
42. SÁNCHEZ, C., ARNT, J., COSTALL, B., DOMENEY, A. M., KELLY, E. AND NAYLOR, R. J.: Sertindole: A limbic selective neuroleptic with potent anxiolytic effects. Drug Dev. Res. 34: 19-29, 1995.
43. WALKER, J. M., BOWEN, W. D., WALKER, F. O., MATSUMOTO, R. R., DE COSTA, B. AND RICE, K. C.: Sigma receptors: Biology and function. Pharmacol. Rev. 42: 355-402, 1990.
44. 2 receptors in motor function. Eur. J. Pharmacol. 231: 61-68, 1993.
45. WOODS, J. H., KATZ, J. L. AND WINGER, G.: Benzodiazepines: Use, abuse, and consequences. Pharmacol. Rev. 44: 151-347, 1992.
46. YOUNG, R. AND JOHNSON, D. N.: A fully automated light/dark apparatus useful for comparing anxiolytic agents. Pharmacol. Biochem. Behav. 40: 739-743, 1991.
47. ZHANG, J., CHIODO, L. A., WETTSTEIN, J. G., JUNIEN, J.-L. AND FREEMAN, A. A.: Repeated administration of sigma ligands alters the population activity of rat midbrain dopaminergic neurons. Synapse 13: 223-230, 1993.